The convergence of biopharmaceuticals and consumer health technology reached an institutional milestone with Eli Lilly and Company’s disclosed interest in purchasing up to $100 million in common stock during the initial public offering of Oura Inc.. Lined up alongside an indicated cornerstone commitment of up to $300 million from Dragoneer Investment Group, the joint commitments represent approximately $400 million, or nearly 19% of the wearable maker’s public offering.

For the better part of a year, the story of AI physiotherapy in the NHS has been told almost entirely in the language of momentum. A Cambridge start-up, Flok Health, secured Class IIa medical device approval under EU regulations in October 2025, becoming the first AI system in Europe cleared to deliver a full care pathway, including diagnostic decisions, without a human clinician supervising each case. The clearance initially covered back pain and sciatica. In August 2026 it

The capitalisation trajectory of OpenEvidence represents one of the most compressed liquidity ascents in the enterprise healthcare technology sector. Within four years of its initial backing, the company evolved from an early-stage clinical retrieval experiment into a decacorn entity valued among the largest private software companies in the world. Between early 2025 and late 2026, OpenEvidence executed a series of high-velocity funding rounds that drove an aggregate fifteenf

How a London communications platform and a Stockholm AI company built the NHS's fastest scaling ambient scribe, and what founders and investors should take from it. Strategic partnerships in HealthTech are announced often and delivered rarely. The press release is easy; the shared roadmap, the aligned commercial incentives and the willingness to let another company sit between you and your customer are hard. Which is why Accurx Scribe, powered by Tandem, deserves attention as

The European digital health and healthcare technology sector is undergoing an institutional realignment. Valued at approximately $96.68 billion in 2025 and projected to expand to $222.22 billion by 2030 at a compound annual growth rate (CAGR) of 18.11%, the market has moved beyond the speculative retail funding cycles that characterised the zero interest rate policy (ZIRP) era. Alongside this software-driven expansion, the broader European medical technology industry maintai

The European healthcare technology landscape has transitioned from the speculative, top line driven environment of the Zero Interest Rate Policy (ZIRP) era into an industrial phase centred on capital efficiency, clinical efficacy and regulatory defensibility. Valued at $96.68 billion in 2025, the European HealthTech sector is projected to reach $222.22 billion by 2030, representing a compound annual growth rate (CAGR) of 18.11%. Concurrently, the European MedTech sector repre

Nelson Advisors LLP is a London headquartered investment banking and corporate finance advisory boutique established in 2023 that operates exclusively within the European Healthcare Technology (HealthTech), Medical Technology (MedTech), and Healthcare Artificial Intelligence (Healthcare AI) sectors. Headquartered at Hale House, 76–78 Portland Place in Marylebone, London, the firm advises clients within the lower to middle market, concentrating on transactions with enterprise